Sign in

You're signed outSign in or to get full access.

Francisco Momo

Senior Equity Research Analyst at Maxim Group

Francisco Momo is a Senior Equity Research Analyst at Maxim Group, specializing in the healthcare and biotechnology sectors with a focus on covering companies such as Equillium, Avenue Therapeutics, and Actinium Pharmaceuticals. He has maintained a strong track record of investment recommendations, consistently ranking in the top quartile on platforms like TipRanks with a success rate above 65% and average returns in double digits. Momo began his analyst career in early 2010s, previously working at firms including Sidoti & Company before joining Maxim Group in 2017. He holds FINRA Series 7, 63, and 86/87 licenses, and is recognized for his expertise and insightful analysis in evaluating clinical-stage biotech investments.

Francisco Momo's questions to Rumble (RUM) leadership

Question · Q1 2025

Francisco Momo inquired about the new brand partnerships with companies like Netflix and Chevron, asking for details on scope and feedback, and also sought clarity on Rumble's M&A strategy.

Answer

CEO Christopher Pavlovski shared that the brand campaign with Netflix was completed and received positive feedback, while campaigns for Chevron and crypto.com are ongoing. He described these partnerships as a 'major win' for Rumble. Regarding M&A, Pavlovski confirmed it is a significant focus for the company but declined to provide further details on potential targets or verticals beyond his prepared remarks.

Ask follow-up questions

Fintool

Fintool can predict Rumble logo RUM's earnings beat/miss a week before the call